Adcetris + chemotherapy first-line treatment for stage III/IV classical Hodgkin lymphoma
The US Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris combines an antibody and drug, allowing the antibody to direct the drug to a target on lymphoma cells known as CD30.
To continue reading this article
Continue reading your article with a eMediNexus account.